Chamomile Tea for Sleep: What the Evidence Shows

Verdict: Weak to Mixed. A few small trials show modest subjective improvement. The mechanism is plausible but the dose in tea may be subtherapeutic. The ritual may matter as much as the compound.

The claim: chamomile tea promotes relaxation and helps you fall asleep. It is one of the oldest sleep remedies in recorded use, recommended by herbalists for centuries and consumed as a bedtime drink across cultures. The clinical evidence is newer and more modest than the tradition.

The claim inventory

Chamomile sleep claims operate on two levels. The explicit pharmacological claim is that chamomile contains compounds (primarily apigenin) that bind to brain receptors involved in sedation, producing a measurable calming effect. The implicit behavioral claim is that the ritual of preparing and drinking warm chamomile tea before bed promotes the transition from wakefulness to sleep. These are different mechanisms with different evidence. Most of the time, when someone says “chamomile tea helps me sleep,” both are operating simultaneously, and separating them is the central challenge of the clinical research.

The marketing language rarely makes this distinction. “Promotes relaxation” could mean receptor binding or ritual calming or both. The ambiguity is useful for the product and unhelpful for the consumer trying to evaluate the evidence.

The mechanism

The primary active compound relevant to sleep is apigenin, a flavonoid found in chamomile flowers that binds to benzodiazepine receptors (specifically the GABA-A receptor complex) in the brain [4]. This is the same receptor family targeted by pharmaceutical sedatives like diazepam, lorazepam, and alprazolam, though apigenin binds with much lower affinity. In animal studies, apigenin produces sedative and anxiolytic effects at sufficient doses. The pharmacological pathway is well-characterized and genuinely plausible.

The dose question is where the plausibility begins to thin. A standardized chamomile extract capsule (270mg, 1.2% apigenin) delivers about 3.2mg of apigenin. A typical cup of chamomile tea contains less, and the amount varies considerably with the tea product, the amount of chamomile used, brewing time, and water temperature. Whether the apigenin in a single cup of tea reaches the threshold for meaningful receptor binding in the human brain has not been directly measured.

There is a pharmacokinetic problem layered on top of the dose problem. Apigenin’s oral bioavailability in humans is not well characterized. Even if a cup of tea contains a measurable amount, the fraction that survives first-pass metabolism in the liver and reaches the brain at sufficient concentration to compete for benzodiazepine binding sites is unknown. The research on chamomile pharmacology [4] describes the receptor binding in vitro, which does not account for absorption, metabolism, and distribution.

Other potentially active compounds in chamomile include bisabolol, chamazulene, and other flavonoids. These have anti-inflammatory and mild anxiolytic properties in preclinical studies, but their contribution to any sleep effect in humans has not been isolated.

What the trials show

Chang and Chen conducted the largest and most cited positive trial: 80 postpartum women with sleep difficulties were randomized to chamomile tea or standard care for two weeks [1]. The chamomile group showed improved sleep quality scores on the PSQI and reduced depression symptoms. This is the strongest positive finding, but the population is specific (postpartum women experience a unique combination of sleep disruption, hormonal changes, and mood disturbance) and the control condition (standard care, not a placebo tea) means participants knew whether they were drinking chamomile. Expectation effects are substantial in sleep research, and an unblinded comparison overstates the pharmacological contribution.

Zick et al. conducted the most methodologically rigorous trial: a pilot RCT with 34 adults with chronic primary insomnia using 270mg chamomile extract (not tea, but standardized capsules) twice daily for 28 days [2]. The extract capsules allowed for more consistent dosing and better blinding than tea would. The results showed “modest” improvement in some sleep diary measures (total sleep time, sleep efficiency), but the improvements did not reach statistical significance. The authors interpreted this as sufficient to warrant a larger trial, which is a careful way of saying the signal was too weak to confirm with this sample size.

Adib-Hajbaghery and Mousavi found that 200mg chamomile extract twice daily improved PSQI sleep quality scores in 60 elderly adults over 28 days compared to placebo [3]. The elderly population is relevant because age-related changes in sleep architecture (less deep sleep, more nocturnal awakenings, earlier circadian phase) create a different baseline than younger adults.

Amsterdam et al., in a secondary analysis of RCT data, found that chamomile extract showed antidepressant effects in people with comorbid anxiety and depression [5]. This is relevant because anxiety and depression are common contributors to insomnia, and an anxiolytic or antidepressant effect could improve sleep indirectly, similar to the ashwagandha pathway.

The ritual question

Chamomile tea is consumed as part of a bedtime ritual: boiling water, steeping, sitting quietly, sipping something warm and aromatic. This ritual itself may promote the transition from wakefulness to sleep by reducing physiological arousal and creating a consistent pre-sleep cue. CBT-I programs emphasize exactly this kind of consistent wind-down behavior as part of stimulus control and sleep hygiene.

The warm liquid component is independently relevant. Warm drinks cause mild peripheral vasodilation, which can lower core body temperature, a physiological signal that promotes sleep onset. The warmth is not specific to chamomile; any warm, non-caffeinated drink would provide the same thermal effect.

Separating the pharmacological effect of chamomile from the behavioral effect of a warm, calming bedtime ritual is methodologically challenging. The studies using extract capsules attempt this separation by removing the ritual component and isolating the chemical effect. Notably, the capsule studies show weaker results than the tea studies, which is suggestive: the ritual may contribute as much or more than the apigenin.

This is not a criticism of chamomile tea as a sleep practice. A ritual that helps people transition to sleep is valuable, regardless of whether it works through receptor binding or behavioral conditioning. It is a criticism of the claim that chamomile is pharmacologically effective as a sleep aid at the doses present in tea.

Where the evidence is stronger

The direction of effect is consistent across the available trials: chamomile, whether as tea or extract, tends to show improvement in subjective sleep quality compared to controls. No trial has found a negative effect. The mechanism is pharmacologically plausible, even if the dose question is unresolved. The safety profile is excellent, with no significant adverse effects reported in any trial and a long history of traditional use without notable harm.

For specific populations (postpartum women, elderly adults), the small positive trials provide some support, though the evidence is not strong enough for a clinical recommendation.

Where the evidence is weaker

No trial has been large enough to detect a clinically meaningful effect with statistical confidence. The Zick trial, the best-designed, found no significant effect. Objective sleep measures (polysomnography, actigraphy) have not been tested with chamomile in a well-powered trial. The blinding problem in tea studies means placebo effects cannot be separated from pharmacological effects.

The apigenin dose problem remains unresolved: a cup of chamomile tea almost certainly delivers less apigenin than the extract capsules used in clinical trials, and even the capsule doses may be subtherapeutic for meaningful benzodiazepine receptor binding in humans.

How it compares to CBT-I

CBT-I produces durable improvement in both subjective and objective sleep measures, with effect sizes that are clinically meaningful: 30-40 minutes reduction in sleep onset latency, improvements in sleep efficiency from the 70s to the high 80s in percentage terms, and remission rates of 70-80% among completers. Chamomile tea, at its best interpretation, produces a small, inconsistent improvement in subjective sleep quality. These are not comparable interventions.

Ironically, the behavioral component of drinking chamomile tea (the ritual, the wind-down, the consistent pre-sleep routine) is more aligned with CBT-I principles than the pharmacological component. If chamomile tea works, it may work partly because it functions as an informal stimulus-control cue: a consistent behavior that signals the brain that sleep is approaching.

The bottom line

Chamomile tea is safe, inexpensive, and part of a bedtime routine that is itself sleep-promoting. The pharmacological evidence for chamomile as a sleep aid is modest at best: a few small trials with inconsistent statistical significance, an unresolved dose question, and an inability to separate the chemical effect from the ritual effect. The tradition is long, the evidence is gentle, and the risk is near zero.

If chamomile tea is part of a consistent wind-down routine, it is a reasonable practice regardless of whether apigenin is reaching your benzodiazepine receptors. If you are buying it expecting it to function like a sleep medication, the evidence does not support that expectation. And if you are choosing between chamomile tea and chamomile extract capsules, the capsules deliver more apigenin but remove the ritual component, and the ritual may be doing more of the actual work than the chemistry.

If you’re struggling with sleep regularly, speak with a GP or pharmacist before adding supplements or medications. For persistent insomnia, AASM guidelines recommend CBT-I as the first-line treatment. The American Academy of Sleep Medicine has a provider finder at sleepeducation.org.